Dr. Ashley E. Ross
Urology (Urology Physician)
675 N Saint Clair St Ste 20-150
Chicago, IL 60611
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Johns Hopkins University School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 447
Licensed in Illinois since 2020, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: Johns Hopkins University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
IL license 036151981 (first issued 2020; active) · MD license D71523
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwestern Medicine Central Dupage Hospital Winfield, IL
- Northwestern Memorial Hospital Chicago, IL
- Northwestern Lake Forest Hospital Lake Forest, IL
- Palos Community Hospital Palos Heights, IL
- Northwestern Medicine Delnor Community Hospital Geneva, IL
Medical groups
- Northwestern Medical Faculty Foundation (4,503 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 447
- Services billed
- 1,344
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Telephone medical discussion with physician, 11-20 minutes | 227 | 185 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 170 | 23 |
| Established patient office or other outpatient visit, 30-39 minutes | 161 | 149 |
| Telephone medical discussion with physician, 21-30 minutes | 140 | 121 |
| Biopsy of prostate gland | 121 | 120 |
| Established patient office or other outpatient visit, 40-54 minutes | 113 | 93 |
| Ultrasound scan of pelvic region through rectum | 102 | 98 |
| 3d radiographic procedure with computerized image postprocessing | 88 | 87 |
| Insertion of needle into vein for collection of blood sample | 67 | 57 |
| New patient office or other outpatient visit, 45-59 minutes | 58 | 58 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Chicago, IL | 211 |
| Finasteride Other prescribers in Chicago, IL | 48 |
| Orgovyx (relugolix) | 31 |
| Imipramine Hcl Other prescribers in Chicago, IL | 23 |
| Alfuzosin Hcl Er (alfuzosin hcl) Other prescribers in Chicago, IL | 19 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Chicago, IL | 16 |
| Ciprofloxacin Hcl Other prescribers in Chicago, IL | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 35 payments worth $36,679 in total to this clinician.
| Pfizer Inc. | $13,233 |
|---|---|
| Progenics Pharmaceuticals, Inc. | $7,015 |
| Bayer HealthCare Pharmaceuticals Inc. | $5,294 |
| Sumitomo Pharma America, Inc. | $3,950 |
| AstraZeneca UK Limited | $2,730 |
| Astellas Pharma Global Development | $2,100 |
| Janssen Biotech, Inc. | $1,655 |
| Blue Earth Diagnostics | $263 |
| Consulting Fee | $19,543 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $14,729 |
| Food and Beverage | $1,611 |
| Travel and Lodging | $798 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Progenics Pharmaceuticals, Inc. Sep 19, 2025 | Consulting Fee PYLARIFY · RADIOPHARMACEUTICAL | $5,705 |
| Sumitomo Pharma America, Inc. Feb 20, 2025 | Consulting Fee ORGOVYX · PROSTATE CANCER | $3,950 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 26, 2025 | Consulting Fee Nubeqa · Oncology | $3,878 |
| Pfizer Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) XTANDI · ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Pfizer Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) XTANDI · ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Pfizer Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) XTANDI · ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| AstraZeneca UK Limited Aug 22, 2025 | Consulting Fee LYNPARZA · Oncology Company’s descriptionResearch Related Service | $2,730 |
| Astellas Pharma Global Development Jun 11, 2025 | Consulting Fee Xtandi · Oncology | $2,100 |
| Pfizer Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) TALZENNA · ONCOLOGY | $2,000 |
| Janssen Biotech, Inc. Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $1,100 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Oct 17, 2025 | Consulting Fee Nubeqa · Oncology | $475 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 15, 2025 | Consulting Fee | $705 |
| Progenics Pharmaceuticals, Inc. Sep 19, 2025 | Consulting Fee PYLARIFY · RADIOPHARMACEUTICAL | $5,705 |
| Progenics Pharmaceuticals, Inc. Sep 19, 2025 | Travel and Lodging PYLARIFY · RADIOPHARMACEUTICAL · travel to BOSTON, MA · in-kind | $122 |
| AstraZeneca UK Limited Aug 22, 2025 | Consulting Fee LYNPARZA · Oncology Company’s descriptionResearch Related Service | $2,730 |
| Progenics Pharmaceuticals, Inc. Aug 12, 2025 | Travel and Lodging PYLARIFY · RADIOPHARMACEUTICAL · travel to BOSTON, MA · in-kind | $323 |
| Progenics Pharmaceuticals, Inc. Aug 12, 2025 | Travel and Lodging PYLARIFY · RADIOPHARMACEUTICAL · travel to BOSTON, MA · in-kind | $302 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 26, 2025 | Consulting Fee Nubeqa · Oncology | $3,878 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 26, 2025 | Travel and Lodging Nubeqa · Oncology · travel to Rosemont, IL · in-kind | $50.83 |
| Astellas Pharma Global Development Jun 11, 2025 | Consulting Fee Xtandi · Oncology | $2,100 |
| Janssen Biotech, Inc. May 21, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $529 |
| Pfizer Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) XTANDI · ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Pfizer Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) XTANDI · ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Pfizer Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) XTANDI · ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Pfizer Inc. Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) TALZENNA · ONCOLOGY | $2,000 |
| Sumitomo Pharma America, Inc. Feb 20, 2025 | Consulting Fee ORGOVYX · PROSTATE CANCER | $3,950 |
| Janssen Biotech, Inc. Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $1,100 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $290,025 in research payments for these studies, mostly to the institutions running them.
- rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
Blue Earth Diagnostics · Recruiting · NCT05852041 - An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
Blue Earth Diagnostics · Recruiting · NCT06813898 - A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America, Inc. · Completed · NCT05467176 - BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned
Bayer HealthCare Pharmaceuticals Inc. - BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy …
Bayer HealthCare Pharmaceuticals Inc. - Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc. · Completed · NCT05605964 - BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.